Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rheumate is a prescription medical food developed by Primus Pharmaceuticals for the clinical dietary management of the metabolic effects and side effects associated with methotrexate (MTX) therapy in patients with rheumatoid arthritis. Methotrexate acts as a folate antagonist by inhibiting the enzyme dihydrofolate reductase, which can lead to folate deficiency and associated toxicities such as gastrointestinal distress, liver dysfunction, and cognitive impairment (often referred to as "MTX fog"). Rheumate contains a specific combination of L-methylfolate (the active form of folate), cobalamin (Vitamin B12), and caffeine. L-methylfolate bypasses the metabolic block created by MTX to support cellular processes, while Vitamin B12 and caffeine are included to help mitigate fatigue and cognitive side effects. It is intended for use under medical supervision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rheumate.